Drugs / MYTX-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05652868 | Mar 2023 → Oct 2025 | non-small cell squamous lung carcinoma | Mythic Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYTX-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05652868 ↗ |
| Modality | Other / unclassified | “MYTX-011 is in a class of medications called antibody drug conjugates (ADCs).” NCT05652868 ↗ |
| Route | Intravenous | “MYTX-011 will be administered as an intravenous infusion every 21 days.” NCT05652868 ↗ |